Skip to main content

Advertisement

Log in

Aberrant hormone production from ovarian neoplasms: Strategies for diagnosis and therapy

  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Syndromes involving peptide or nonsex steroid hormone secretion due to aberrantly located tumors are rare. We report a collected series of 16 patients with ectopic hormone production from ovarian neoplasms, including 3 patients recently encountered at our institution as well as 13 additional cases identified in the recent literature. These tumors included 2 insulin-producing ovarian carcinoids, 1 ACTH-producing pituitary adenoma within a benign ovarian cystic teratoma, 2 cortisol-producing ovarian neoplasms, 8 gastrin-producing ovarian cystadenomata or cystadenocarcinomata, and 3 thyroxine-producing ovarian strumal carcinoids. All patients presented with syndromes of hormone excess. Only 62% of all tumors were localized preoperatively. Following ovarian resection, 87% of patients remained disease-free with a median follow-up period of 1.5 years. In addition to ovariectomy, 8 additional unnecessary ablative procedures were performed in 7 patients. These included distal pancreatectomy, pancreaticoduodenectomy, adrenalectomy, total gastrectomy, selective vagotomy, and subtotal thyroidectomy. Failure to localize the ovarian neoplasm preoperatively was associated with a significantly higher risk of subsequent unnecessary ablative procedures. Because of the potential for the ovary to act as a source of aberrant hormone secretion, we recommend complete preoperative evaluation of the pelvis in female patients presenting with nonlocalizable endocrine tumors.

Résumé

Les syndromes concernant la sécrétion d'hormones peptidique ou stéroïde nonsexuelle due à des tumeurs ectopiques sont rares. Nous rapportons une série de 16 patientes avec une production d'hormone ectopique provenant de néoplasmes ovariens, comprenant 3 patientes récemment soignées dans notre établissement ainsi que 13 cas supplémentaires relevés dans la littérature récente. Ces tumeurs comprennent 2 tumeurs carcinoïdes ovariennes productrices d'insuline, 1 adénome hypophysaire producteur d'ACTH à l'intérieur d'un tératome cystique ovarien bénin, 2 néoplasmes ovariens producteurs de cortisol, 8 cystadénomes ou cystadénocarcinomes ovariens producteurs de gastrine, et 3 carcinoïdes ovariens strumaux producteurs de thyroxine. Toutes les patientes avaient des syndromes d'hyperproduction hormonale. Soixante-deux pour cent seulement des tumeurs avaient été localisées en préopératoire. Après ovariectomie, 87% des patientes étaient apparamment sans récidive avec un suivi médian d'un an et demi. Cependent, outre l'ovariectomie, 8 interventions supplémentaires non nécessaires ont été accomplis chez 7 patientes. Celles-ci comprenaient: pancréatectomie distale, duodénopancréatectomie, surrénalectomie, gastrectomie totale, vagotomie sélective, et thyroïdectomie subtotale. L'impossibilité de localiser le néoplasme ovarien en période préopératoire était associée à un risque notoirement plus grand de faire une résection inutile. Compte tenu de la possibilité pour l'ovaire de se comporter en producteur de sécrétion ectopique d'hormone, nous recommandons un examen complet préopératoire du bassin chez les femmes se présentant avec des tumeurs endocrines non localisables.

Resumen

Los síndromes relacionados con la secreción de péptidos o de hormonas esteroideas no sexuales por tumores de ubicación aberrante ocurren infrecuentemente. En este artículo reportamos una serie de 16 pacientes con producción hormonal ectópica por neoplasmas ováricos, la cual incluye 3 pacientes vistos recientemente en nuestra institución y 13 identificados en la literatura médica de los últimos años. El grupo incluye 2 carcinoides ováricos productores de insulina, 1 adenoma pituitario productor de ACTH, 2 neoplasmas ováricos productores de cortisol, 8 cistadenomas o cistadenocarcinomas ováricos productores de gastrina, y 3 carcinoides ováricos estrumales productores de tiroxina. Todas las pacientes se presentaron con síndromes de exceso hormonal. En sólo el 62% de los tumores se pudo establecer la ubicación anatómica en la fase preoperatoria. Después de realizada la resección del ovario, 87% de las pacientes permanecieron libres de enfermedad en el período de seguimiento, que fue de 1.5 años en promedio. Además de la resección ovárica, se practicaron otros 8 procedimientos adicionales innecesarios en 7 pacientes. Estos incluyeron pancreatectomía distal, pancreatoduodenectomía, adrenalectomía, gatrectomía total, vagotomía selectiva, y tiroidectomía subtotal. La falla en la localización preoperatoria del neoplasma ovárico apareció asociada con un riesgo aumentado de ulteriores procedimientos quirúrgicos innecesarios. En vista de la potencialidad del ovario de actuar como fuente de secreción hormonal aberrante, nosotros recomendamos una completa evaluación de la pelvis en las pacientes femeninas en quienes se diagnostiquen tumores endocrinos no localizables.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Fraker, D.L., Norton, J.A.: Localization and resection of insulinomas and gastrinomas. J. Am. Med. Assoc.259:3601, 1988

    Google Scholar 

  2. Katz, B.L., Aufses, A.H., Rayfield, E., Mitty, H.: Preoperative localization and intraoperative glucose monitoring in the management of patients with pancreatic insulinoma. Surg. Gynecol. Obstet.163:509, 1986

    Google Scholar 

  3. Norton, J.A., Doppman, J.L., Collen, M.J., Harmon, J.W., Maton, P.N., Gardner, J.D., Jensen, R.T.: Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome. Ann. Surg.204:468, 1986

    Google Scholar 

  4. Sporrong, B., Falkmer, S., Robboy, S.J., Alumets, J., Hakanson, R., Ljungberg, O., Sundler, F.: Neurohormonal peptides in ovarian carcinoids. Cancer49:68, 1982

    Google Scholar 

  5. Sporrong, B., Alumets, J., Clase, L., Falkmer, S., Hakanson, R., Ljungberg, O., Sundler, F.: Neurohormonal peptide immunoreactive cells in mucinous cystadenomas and cystadenocarcinomas of the ovary. Virchows Arch. [A]392:271, 1981

    Google Scholar 

  6. Axiotis, C.A., Lippes, H.A., Merino, M.J., de Lanerolle, N.C., Stewart, A.F., Kinder, B.: Corticotroph cell pituitary adenoma within an ovarian teratoma: A new cause of Cushing's syndrome. Am. J. Surg. Pathol.11:218, 1987

    Google Scholar 

  7. Marieb, N.J., Spangler, S., Kashgarian, M., Heimann, A., Schwartz, M.L., Schwartz, P.E.: Cushing's syndrome secondary to ectopic cortisol production by an ovarian carcinoma. J. Clin. Endocrinol. Metab.57:737, 1983

    Google Scholar 

  8. Long, T.T., Barton, T.K., Draffin, R., Reeves, W.J., McCarty, K.S.: Conservative management of the Zollinger-Ellison syndrome: Ectopic gastrin production by an ovarian cystadenoma. J. Am. Med. Assoc.243:1837, 1980

    Google Scholar 

  9. Cocco, A.E., Conway, S.J.: Zollinger-Ellison syndrome associated with ovarian mucinous cystadenocarcinoma. N. Engl. J. Med.293:485, 1975

    Google Scholar 

  10. Julkunen, R., Partanen, S., Salaspuro, M.: Gastrin-producing ovarian mucinous cystadenoma. J. Clin. Gastroenterol.5:67, 1983

    Google Scholar 

  11. Bollen, E.C.M., Lamers, C.B., Jansen, J.B., Larsson, L.I., Joosten, H.J.M.: Zollinger-Ellison syndrome due to a gastrin-producing ovarian cystadenocarcinoma. Br. J. Surg.68:776, 1981

    Google Scholar 

  12. Primrose, J.N., Maloney, M., Wells, M., Bulgim, O., Johnston, D.: Gastrin-producing ovarian mucinous cystadenomas: A cause of the Zollinger-Ellison syndrome. Surgery104:830, 1988

    Google Scholar 

  13. Heyd, J., Livni, N., Hérbet, D., Mor-Yosef, S., Glaser, B.: Gastrin-producing ovarian cystadenocarcinoma: Sensitivity to secretin and SMS 201-995. Gastroenterology97:464, 1989

    Google Scholar 

  14. Matson, P.N., Mackem, S.M., Norton, J.A., Gardner, J.D., O'Dorisio, T.M., Jensen, R.T.: Ovarian carcinoma as a cause of Zollinger-Ellison syndrome. Gastroenterology97:468, 1989

    Google Scholar 

  15. March, D.E., Desai, A.G., Park, C.H., Hendricks, P.J., Davis, P.S.: Struma ovarii: Hyperthyroidism in a postmenopausal woman. J. Nucl. Med.29:262, 1988

    Google Scholar 

  16. Robboy, S.J., Scully, R.E.: Strumal carcinoid of the ovary: An analysis of 50 cases of a distinctive tumor composed of thyroid tissue and carcinoid. Cancer46:2019, 1980

    Google Scholar 

  17. Chetkowski, R.J., Judd, H.L., Jagger, P.I., Nieberg, R.K., Chang, J.: Autonomous cortisol secretion by a lipoid cell tumor of the ovary. J. Am. Med. Assoc.254:2628, 1985

    Google Scholar 

  18. Morgello, S., Schwartz, E., Horwith, M., King, M.E., Gorden, P., Alonso, D.R.: Ectopic insulin production by a primary ovarian carcinoid. Cancer61:800, 1988

    Google Scholar 

  19. Filipi, C.J., Higgins, G.A.: Diagnosis and management of insulinoma. Am. J. Surg.125:231, 1973

    Google Scholar 

  20. Miyazaki, K., Funakoshi, A., Nishihara, S., Wasada, T., Koga, A., Ibayashi, H.: Aberrant insulinoma in the duodenum. Gastroenterology90:1280, 1986

    Google Scholar 

  21. Kvols, L.K., Buck, M., Moertel, C.G., Schutt, A.J., Rubin, J., O'Connell, M.J., Hahn, R.G.: Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann. Int. Med.107:162, 1987

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leach, S.D., LaMorte, A.I., True, L.D. et al. Aberrant hormone production from ovarian neoplasms: Strategies for diagnosis and therapy. World J. Surg. 14, 335–340 (1990). https://doi.org/10.1007/BF01658520

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01658520

Keywords

Navigation